Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalFRA:IC7 78 Debt-to-Equity is 0.59 as of Jun. 2026, which is 3% below its 10-year median of 0.61. GuruFocus rates FRA:IC7 with a GF Score™ of 78/100 and a GF Value™ of €102.42 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 700 Medical Devices & Instruments companies, ICU Medical ranks worse than 74.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ICU Medical's Debt-to-Equity or its related term are showing as below:
FRA:IC7'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.61 Max: 0.86
Current: 0.59
During the past 13 years, the highest Debt-to-Equity Ratio of ICU Medical was 0.86. The lowest was 0.00. And the median was 0.61.
FRA:IC7's Debt-to-Equity is ranked worse than 74.14% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:IC7: 0.59
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ICU Medical Debt-to-Equity Related Terms
ICU Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ICU Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IC7 vs NVST, MMSI, MMED: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ICU Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (FRA:IC7) has a Debt-to-Equity of 0.59 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ICU Medical and its competitors. This is near median its historical median of 0.61. According to the industry distribution chart, ICU Medical ranks #519 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is ICU Medical's Debt-to-Equity too high?
ICU Medical's current Debt-to-Equity of 0.59 is near median its 10-year median of 0.61. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. ICU Medical's value of 0.59 is 156.5% above this industry median. Based on the distribution chart, ICU Medical ranks #519 out of 700 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ICU Medical has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Debt-to-Equity compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #519 out of 700 companies for Debt-to-Equity. This places ICU Medical in the lower half of its industry. The industry median Debt-to-Equity is 0.23. ICU Medical's value of 0.59 is 156.5% above this benchmark. While the company's 10-year median is 0.61 vs. the industry median of 0.23, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current Debt-to-Equity of 0.59 is 156.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current Debt-to-Equity is 0.59, which is near median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (FRA:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €102.42, compared to a current price of €159.00 — trading 55.2% above its estimated fair value. The current Debt-to-Equity is 0.59, which is near median its 10-year median of 0.61 and 156.5% above the Medical Devices & Instruments industry median of 0.23. ICU Medical's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ICU Medical (FRA:IC7), the current Debt-to-Equity is 0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (FRA:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €159.00 is trading 55.2% above its estimated GF Value™ of €102.42.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for FRA:IC7:
Debt-to-Equity: 0.59 (near median its 10-year median of 0.61)
GF Value™: €102.42 vs. price of €159.00 (55.2% above fair value)
Industry Position: 156.5% above the Medical Devices & Instruments median (#519 of 700)
No single metric tells the full story. See the FRA:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
78GF Score
Get the complete analysis for FRA:IC7
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IC7 has been successfully added to your 
